Search results

AstraZeneca favours buyouts to offload German DB liabilities

2025-11-25T10:00:00Z

Pharmaceutical group rules out consolidating its German pension plans due to impracticalities

Stewardship case study: AstraZeneca

Reference Hub2024-10-25T18:12:00Z By Federated Hermes

EOS identified robust succession planning for both the CEO and the chair as integral to the achievement of a long-term strategy.

EOS 2024 Annual Review

Reference Hub2025-02-28T11:41:00Z By Federated Hermes

EOS publishes 2024 Annual Review, with full engagement and voting highlights.

Funding Solutions completes German pension buyout as market momentum builds

2025-05-09T09:00:00Z

The latest pension buyout deal is with automotive supplier Sinterwerke Herne

UK roundup: Aon Hewitt, LAPFF, Astrazeneca

2013-04-15T14:45:00Z

UK – Aon Hewitt predicts UK funds to increasingly rely on bonds, alternative portfolios.

Wellcome Trust complains to chancellor over possible AstraZeneca deal

2014-05-12T14:12:00Z

Foundation raises ‘major concerns’ over proposed takeover of Anglo-Swedish pharmaceutical AstraZeneca by US multinational Pfizer

AstraZeneca pension fund agrees £2.5bn longevity swap deal

2013-12-17T10:28:00Z

News comes week after Carillion announces €1bn longevity deal with Deutsche Bank

Nuveen Real Estate completes €35m green loan for Amsterdam life sciences development

Reference Hub2024-02-07T17:18:00Z By Nuveen Real Estate (Europe)

Nuveen Real Estate, one of the largest investment managers in the world with $149 billion of assets under management, has agreed to provide a €35m senior secured loan to Breakthrough Properties, a joint venture of Tishman Speyer and Bellco Capital, to finance the acquisition and construction of One Helix, a state-of-the-art life science asset in Amsterdam.

The vaccine is a binary event for the markets, not for the economy

Reference Hub2020-12-01T09:58:00Z By Amundi

Since the announcements of the discovery of a very effective vaccine, first by Pfizer-BioNTech and then by Moderna and AstraZeneca, the horizon has opened up. Investors are beginning to dream of a world immune to Covid-19. But one swallow doesn’t make a spring. Many unknowns remain (see p.4) and the Covid-19 crisis will leave lasting traces in the economy going forward.

AstraZeneca opts for flexibility

February 2002 (Magazine)

AstraZeneca equity cut not influenced by Boots

2002-01-15T04:37:00Z

UK – The recent asset allocation shift that saw the £4.2bn (€6.8bn) AstraZeneca pension fund reduce its equity holdings by five percent in favour of fixed income was not influenced by the Boots pension fund getting rid of its entire equity portfolios last October.

Carbon-based pay incentives falling short of investor demands, says report

2023-03-16T15:08:00Z

There needs to be more ambition to implement carbon targets robustly and effectively, using the power of incentives to support the push for net zero

Handelsbanken wins SKr920m AstraZeneca bond brief

2001-12-18T03:59:00Z

SWEDEN – Anglo-Swedish pharmaceutical company, AstraZeneca has appointed Handelsbanken to run a new Swedish fixed income portfolio within its SKr2.3bn (€243.3m) pension fund....

Healthcare investing: Get ready for the next pandemic

April 2022 (Magazine)

The world will have to collaborate on many fronts to ensure preparedness for the next global health crisis.

Pension funds call on pharmas to improve vaccine distribution

2022-01-07T14:10:00Z

They threaten to vote against executive remuneration proposals and board appointments if insufficient action is taken

A closer look at European equities

Reference Hub2024-10-01T00:16:00Z By STOXX

Interview with Arun Singhal, Global Head of Product Management at STOXX.

AstraZeneca creates SEK2.2bn Swedish pension fund

2001-09-03T11:45:00Z

SWEDEN – The Swedish arm of pharmaceutical multinational AstraZeneca is to transfer around SEK2.2bn (e232m) from its balance sheet into a pension foundation, which could be outsourced to external managers as early as the beginning of next year.....

M&A medicine

June 2014 (Magazine)

The debate about Pfizer’s proposed takeover of the UK’s AstraZeneca – which should have resolved itself by the time you read this – reminds us that there are some big unanswered questions relating to institutional investors and M&A activity.

Shrinking assets and falling long-term rates worry Swedish pensions sector

2020-03-24T15:25:00Z

“We can only hope we succeed in halting the contagion,” says PRI Pensionsgaranti CEO

CCLA launches global company mental health benchmark

2022-10-10T14:02:00Z

Plus: Federated Hermes appointed for pair of fixed income mandates